A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination. - Dixit KS; Kumthekar P; Lukas RV; Williams A; Tate MC; Chandler JP; Jamshidi P; Helenowski I; Zhang H; Bloch O; Raizer JJ (Journal of neuro-oncology, 2026)